[{"data":1,"prerenderedAt":254},["ShallowReactive",2],{"$f2dn8g7ss83ddx":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":56,"top_diseases":83,"top_companies":115,"key_results":141,"trends":231,"previous_editions":240,"comparison":244,"highlighted_classes":253},1,"aan-2026","AAN","aan","AAN Annual Meeting 2026",2026,"Neurology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},3275,1138,187,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},25,9,27,11,6,90,[24,28,31,34,38,41,44,48,52,54],{"name":25,"count":26,"share":27},"GR",80,7,{"name":29,"count":30,"share":27},"FCGRT",75,{"name":32,"count":33,"share":21},"CD20",63,{"name":35,"count":36,"share":37},"C1Q",50,4,{"name":39,"count":40,"share":37},"FcγR",49,{"name":42,"count":43,"share":37},"PLG",46,{"name":45,"count":46,"share":47},"NaV",30,3,{"name":49,"count":50,"share":51},"DDC",26,2,{"name":53,"count":50,"share":51},"DRD",{"name":55,"count":17,"share":51},"CD19",[57,61,65,69,72,75,77,80],{"name":58,"count":59,"share":60},"Small molecules",709,62,{"name":62,"count":63,"share":64},"Monoclonal antibodies",325,29,{"name":66,"count":67,"share":68},"Non-antibody therapeutic proteins",94,8,{"name":70,"count":71,"share":27},"Blood, tissue and cell-derived products",79,{"name":73,"count":74,"share":47},"Peptides",33,{"name":76,"count":17,"share":51},"Cell therapies",{"name":78,"count":79,"share":51},"Oligonucleotide and RNA therapeutics",20,{"name":81,"count":82,"share":4},"Carbohydrate, lipid and polymer therapeutics",17,[84,88,91,94,97,101,104,107,110,112],{"name":85,"count":86,"share":87},"ischemic stroke",112,10,{"name":89,"count":90,"share":21},"Alzheimer's disease (AD)",68,{"name":92,"count":93,"share":21},"multiple sclerosis (MS)",66,{"name":95,"count":96,"share":21},"myasthenia gravis (MG)",64,{"name":98,"count":99,"share":100},"Parkinson's disease (PD)",58,5,{"name":102,"count":103,"share":100},"epilepsy",54,{"name":105,"count":106,"share":37},"migraine",41,{"name":108,"count":109,"share":47},"Neuromyelitis Optica Spectrum Disorder (NMOSD)",36,{"name":111,"count":46,"share":47},"chronic inflammatory demyelinating polyneuropathy (CIDP)",{"name":113,"count":114,"share":51},"Autoimmune Encephalitis (AE)",28,[116,119,122,125,127,130,132,135,137,139],{"name":117,"count":118,"share":18},"Genentech",104,{"name":120,"count":121,"share":27},"Pfizer",85,{"name":123,"count":124,"share":37},"ADMA Biologics",48,{"name":126,"count":106,"share":37},"Merck",{"name":128,"count":129,"share":47},"Bristol Myers Squibb",35,{"name":131,"count":129,"share":47},"GSK",{"name":133,"count":134,"share":47},"UCB",31,{"name":136,"count":64,"share":47},"Eisai",{"name":138,"count":114,"share":51},"Roche",{"name":140,"count":17,"share":51},"argenx",[142,150,158,165,172,180,187,194,202,209,216,223],{"title":143,"drug":144,"company":117,"phase":146,"disease":147,"finding":148,"url":149},"ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease",{"name":145,"slug":145},"ocrelizumab","Phase 3","primary progressive multiple sclerosis (PPMS)","The percentage of ocrelizumab and placebo patients with 12W-cCDP was 32.7% vs 40.4% (hazard ratio [HR] [95% CI]: 0.70 [0.57-0.86]; risk reduction [RR], 30%; P =0.0007); 16.7% vs 24.9% on 9HPT (RR, 41%; P=0.0002) and 23.0% vs 30.8% on EDSS (RR, 33%; P =0.0013).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215551",{"title":151,"drug":152,"company":154,"phase":146,"disease":155,"finding":156,"url":157},"Efficacy and Safety of Ecopipam for Tourette Syndrome: Results from a Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Trial",{"name":153,"slug":153},"ecopipam","Emalex Biosciences","Tourette syndrome (TS)","The risk of relapse was significantly reduced in the ecopipam group compared with placebo in the pediatric (hazard ratio [HR]=0.5 [0.3, 0.8]; P=0.008) and pediatric plus adult (HR=0.5 [0.3, 0.8]; P=0.005) populations.","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000216955",{"title":159,"drug":160,"company":162,"phase":146,"disease":92,"finding":163,"url":164},"Effects of Tolebrutinib on Progression Independent of Relapse Activity in the Phase Three GEMINI Relapsing MS Trials",{"name":161,"slug":161},"tolebrutinib","Sanofi","Although tolebrutinib was not superior to teriflunomide in reducing ARR, the percentage of participants with 6mCDW was 8.3% with tolebrutinib and 11.3% with teriflunomide (hazard ratio, 0.71; 95% CI, 0.53–0.95).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215455",{"title":166,"drug":167,"company":169,"phase":146,"disease":105,"finding":170,"url":171},"Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: Results from the Head-to-head TEMPLE Trial",{"name":168,"slug":168},"atogepant","AbbVie","A higher proportion of participants experienced TEAEs with topiramate compared to atogepant (88.8% vs 76.9%).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215537",{"title":173,"drug":174,"company":176,"phase":146,"disease":177,"finding":178,"url":179},"The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One",{"name":175,"slug":175},"oveporexton","Takeda","narcolepsy type 1 (NT1)","The most common TEAEs with oveporexton were pollakiuria (43 [61.4%]) and insomnia (40 [57.1%]).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215556",{"title":181,"drug":182,"company":184,"phase":146,"disease":102,"finding":185,"url":186},"Efficacy and Safety of Adjunctive Cenobamate for the Treatment of Primary Generalized Tonic-clonic Seizures in Adults and Adolescents",{"name":183,"slug":183},"cenobamate",null,"Among the 161 patients (placebo, n=78; cenobamate, n=83) analyzed during the maintenance-phase, the ≥50% responder rate was 71.1% for cenobamate (vs 51.3% placebo, P =0.01); 43.4% of cenobamate-treated patients were seizure-free (vs 20.5% placebo, P =0.002).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215694",{"title":188,"drug":189,"company":191,"phase":146,"disease":177,"finding":192,"url":193},"Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results From the Phase Three SYMPHONY Trial",{"name":190,"slug":190},"reboxetine","Axsome Therapeutics","At week 5, AXS-12 significantly improved CGI-S versus placebo (LS mean difference [95% CI]=0.72 [0.29, 1.16]; p=0.001).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000217437",{"title":195,"drug":196,"company":184,"phase":146,"disease":113,"finding":200,"url":201},"Phase 3 Clinical Study of IVIG for Efficacy and Safety in Patients with Autoimmune Encephalitis",{"name":197,"slug":198,"named_as":199},"immune globulin","immune-globulin","IVIG","The proportion of responders was 57.1% (95% CI: 18.405, 90.101) in the IVIG group and 0% (95% CI: 0.000, 70.706) in the control group.","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000212984",{"title":203,"drug":204,"company":206,"phase":146,"disease":95,"finding":207,"url":208},"Rapid and Sustained Efficacy of Subcutaneously Administered Cemdisiran Without Complete Complement Blockade in Patients with Generalized Myasthenia Gravis (gMG): Primary Efficacy and Safety Results from the Phase Three NIMBLE Trial",{"name":205,"slug":205},"cemdisiran","Regeneron Pharmaceuticals","TEAEs occurred in 69.2% ( cemdisiran ), 81.3% (combination) , and 77.1% (placebo).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215277",{"title":210,"drug":211,"company":213,"phase":146,"disease":105,"finding":214,"url":215},"Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Children and Adolescents: Outcomes from Two Randomized, Double-blind, Placebo-controlled, Phase 3 Studies",{"name":212,"slug":212},"fremanezumab","Teva Pharmaceutical Industries","In the EM study, MHD reduction was significantly greater with fremanezumab versus placebo (–2.6 vs –1.5; p=0.0172), as was the ≥50% MMD response rate (47.2% vs 27.0%; p=0.0016).","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000214996",{"title":217,"drug":218,"company":220,"phase":146,"disease":98,"finding":221,"url":222},"Comparative Efficacy of Opicapone and Entacapone in the Management of Motor Fluctuations in Parkinson’s Disease",{"name":219,"slug":219},"opicapone","Bial","A higher proportion of patients on OPC vs ENT showed minimally, much or very much improved Clinician (73% vs 50.9% respectively, p =0.0070) and Patient (72.1% vs 52.5% respectively, p =0.0091) Global Impression of Change scores.","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215249",{"title":224,"drug":225,"company":136,"phase":146,"disease":228,"finding":229,"url":230},"Interpreting Adverse Events of Somnolence With Lemborexant in Clinical Trials",{"name":226,"slug":226,"named_as":227},"lemborexant","LEM10","Insomnia","Few participants discontinued due to somnolence (PBO: 0.6%; LEM5: 1.1%; LEM10: 2.3%); most TEAE-S were mild and transient.","https:\u002F\u002Fdoi.org\u002F10.1212\u002FWNL.0000000000215280",{"summary":232,"bullets":234},[233],"Small molecules, the most frequent modality, accounted for 62% of drug-linked abstracts, up from 58% in 2025. Carbohydrate, lipid and polymer therapeutics (1%) were new to the top modalities compared with 2025. CD19 (2%) was new to the top targets compared with 2025.",[235,236,237,238,239],"GR was the most frequent target (7% of drug-linked abstracts).","Ischemic stroke was the most frequent disease (10%).","Genentech had the largest company share (9%).","The edition had 3275 abstracts, up 7% from 3066 in 2025.","Monoclonal antibodies were the next most frequent modality (29%).",[241],{"year":242,"abstracts":243},2025,3066,{"previous_year":242,"abstracts":245,"targets":247,"modalities":248,"new_in_top_targets":251,"new_in_top_modalities":252},{"previous":243,"current":13,"change_pct":27,"direction":246},"rose",[],[249],{"name":58,"count":59,"share":60,"previous_count":250,"previous_share":99,"direction":246},572,[55],[81],[],1793970603088]